Fig. 2From: Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching studyKaplan–Meier curves of time to progression for patients with advanced hepatocellular carcinoma who received the treatment of TACE–apatinib or TACE-Sorafenib after propensity score matchingBack to article page